Clinical Trial Details


Research Study Summary

Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS) needed for a clinical research trial


A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study To Access The Efficacy And Safety Of Three Different Doses (275, 550, and 1100 MG) Of Rifaximin Administered BID For Either Two Or Four Weeks in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

Study visits include a screening visit and 8 office visits over 16 weeks.

Major Inclusion Criteria:
  • Female or Male at least 18 years old
  • Irritable Bowel Syndrome presenting with diarrhea associated IBS symptoms
As part of the study, you will receive at no cost:
  • Study-related medical care and exams
  • Study-related medication
  • Compensation up to $300.00 for time and travel

Call today if you would like to learn more about this study and to find out if you qualify.

To Learn more

CW ID: 84972
Date Last Changed: July 25, 2013

Clinical Trial Snapshot

Both Male and Female
18 and up
Overall Status
16 Weeks
Facility Type
Up to $300


Silvia Sanchez, Patient Recruitment Coordinator
Anaheim Clinical Trials (ACT)
1211 W. La Palma Ave., Suite 602
Anaheim, CA 92801
Phone: 714-778-1309 x.227
Fax: 714-778-0667

View Map

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.